Empo Health is a technology company.
Empo Health has raised $7.0M across 1 funding round.
Key people at Empo Health.
Empo Health has raised $7.0M in total across 1 funding round.
Empo Health has raised $7.0M in total across 1 funding round.
Empo Health's investors include IGNIA Partners, SeaX Ventures, SOSV, Story Ventures, Ulu Ventures.
Empo Health is a healthcare technology company that develops in-home monitoring devices for diabetic patients at risk of foot ulcers (DFUs), which can lead to hospitalization, amputation, and early death.[2][3][4] Its flagship products—the FDA-listed Empo® Footprint imaging scale and the HIPAA-compliant Empo® Remote Health Link digital portal—enable daily at-home foot imaging and weight measurement, with cloud-based analysis sending alerts to providers for early intervention.[2][3][4] Serving diabetic patients with neuropathy and their podiatrists or primary care providers, Empo solves the challenge of inconsistent monitoring by integrating seamlessly into routines, like stepping on a bathroom scale, to improve outcomes and reduce healthcare costs.[2][3][4][7] Founded in 2020 and based in San Bruno, California, the company raised $7M in funding to support its commercial launch, backed by VC investors, angels, and SBIR grants, showing strong growth momentum amid rising demand for remote patient monitoring (RPM).[4]
Empo Health was incorporated in 2020 by MIT- and Stanford-trained technical co-founders Anuj Khandelwal (CEO) and Eric Dahlseng (Chief Product Officer), based in the San Francisco Bay Area.[4][6] The idea emerged from recognizing that over 20 million U.S. adults with diabetic neuropathy struggle with regular foot monitoring, despite evidence that consistent checks reduce amputations.[3][6] Early traction included building an automated foot inspection system using high-resolution imaging, computer vision, and cloud processing, validated by clinical advisors like Dr. Richard Silverstein (former podiatry head at Harford Memorial Hospital) and Dr. Bryan Markinson (Chief of Podiatric Medicine at Mount Sinai).[3][6] Pivotal moments feature a $7M funding round announced for market launch and partnerships with podiatry experts, positioning it as a leader in DFU prevention.[4]
Empo Health rides the remote patient monitoring (RPM) wave, fueled by telehealth expansion post-COVID and AI advancements in computer vision for home diagnostics.[2] Timing is ideal amid a diabetes epidemic—20M+ U.S. cases—and DFU burdens costing billions in hospitalizations, where RPM enables personalized care, quick responses, and resource optimization.[2][3] Market forces like value-based care, payer incentives for prevention, and FDA-cleared wearables favor scalable solutions like Empo's, which democratize access for homebound patients.[4] It influences the ecosystem by pioneering DFU-specific RPM, inspiring similar devices in chronic care and partnering with hospitals like Memorial Hermann's affiliates, potentially lowering amputation rates and setting standards for consumer-grade medtech.[2][4]
Empo Health is poised to scale commercially post-$7M raise, expanding prescriptions via podiatrists and payers focused on cost savings from prevented amputations.[4] Trends like AI-enhanced RPM, aging populations, and home health integration will accelerate adoption, with potential for EHR interoperability and global reach.[2][4] Its influence may evolve into a DFU standard, influencing medtech by proving simple hardware + software combos drive outcomes—ultimately empowering more patients to stay mobile and reduce systemic healthcare strain, fulfilling its mission from day one.[3][4][6]
Key people at Empo Health.
Empo Health has raised $7.0M across 1 funding round. Most recently, it raised $7.0M Venture Round in June 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2025 | $7.0M Venture Round | IGNIA Partners, SeaX Ventures, SOSV, Story Ventures, Ulu Ventures |
